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Abstract
Fe absorption from water-soluble forms of Fe is inversely proportional to Fe status in humans. Whether this is true for poorly soluble Fe
compounds is uncertain. Our objectives were therefore (1) to compare the up-regulation of Fe absorption at low Fe status from ferrous
sulphate (FS) and ferric pyrophosphate (FPP) and (2) to compare the efficacy of FS with FPP in a fortification trial to increase body Fe
stores in Fe-deficient children v. Fe-sufficient children. Using stable isotopes in test meals in young women (n 49) selected for low and
high Fe status, we compared the absorption of FPP with FS. We analysed data from previous efficacy trials in children (n 258) to determine
whether Fe status at baseline predicted response to FS v. FPP as salt fortificants. Plasma ferritin was a strong negative predictor of Fe bioa-
vailability from FS (P,0·0001) but not from FPP. In the efficacy trials, body Fe at baseline was a negative predictor of the change in body Fe
for both FPP and FS, but the effect was significantly greater with FS (P,0·01). Because Fe deficiency up-regulates Fe absorption from FS
but not from FPP, food fortification with FS may have relatively greater impact in Fe-deficient children. Thus, more soluble Fe compounds
not only demonstrate better overall absorption and can be used at lower fortification levels, but they also have the added advantage that,
because their absorption is up-regulated in Fe deficiency, they innately ‘target’ Fe-deficient individuals in a population.
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Fe fortification of foods can be an effective strategy to
control Fe deficiency(1). The relative bioavailability (RBV)
of an Fe compound – its estimated percentage absorption
relative to the absorption of ferrous sulphate (FS) – is used
to rank Fe fortification compounds and to set food fortifica-
tion levels(2,3). Ferric pyrophosphate (FPP) is generally less
than half as well absorbed as FS(2,3). On this basis, the
WHO recommends FS as a first-choice Fe fortificant and
recommends that if FPP is used, the fortification level
should be doubled(3).
The absorption of dietary Fe is dependent on Fe status;
the fractional absorption of an oral Fe dose is greater in Fe-
deficient individuals than in Fe-sufficient individuals(4).
This is a primary homeostatic mechanism controlling
body Fe stores in humans and appears to be regulated
by circulating hepcidin concentrations(5). It has been
traditionally assumed that up-regulation occurs for all Fe
compounds equally. However, a recent small study has
suggested that the absorption of FS in women with poor
Fe status was up-regulated to a greater degree than
FPP(6). It was unclear whether this effect was due to the
special form of FPP – small particles coated with emulsi-
fiers – used in the study; the findings need confirmation
in studies with commercial FPP. But if true, the RBV of
an Fe compound may depend on the Fe status of the indi-
vidual/population. This would limit the use of RBV to rank
Fe fortification compounds and to adjust fortification
levels. It would also argue strongly for the use of soluble
compounds in fortified foods in populations with high
rates of Fe deficiency.
Therefore, the aim of the present study was to (1) use
stable Fe isotopes to compare the up-regulation of Fe
absorption at low Fe status from FS and FPP, (2) determine
whether the RBV of FPP varies with Fe status and (3)
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compare the relative efficacy of FPP and FS as fortificants
to increase body Fe stores in Fe-deficient children v. Fe-
sufficient children.
Materials and methods
Study 1: stable isotope studies
Subjects. A total of forty-nine apparently healthy young
women were enrolled: (1) twenty-five women with low
Fe status as defined by a plasma ferritin concentration
,25mg/l with or without anaemia and (2) twenty-four
women with Fe sufficiency as defined by plasma ferritin
.40mg/l and a normal Hb concentration ($120 g/l).
Inclusion criteria for both groups were as follows: age
18–40 years; no chronic medical illnesses or medications;
body weight #65 kg; non-pregnant and not planning preg-
nancy; no blood donation within the previous 4 months; a
C-reactive protein concentration ,50 mg/l (to exclude the
potential confounding effect of inflammation). Sample size
calculations indicated that twenty-four subjects should be
included in both the low and high Fe status groups,
based on 80 % power to detect a 50 % difference in Fe
absorption with a standard deviation of 8·2 % for log-trans-
formed absorption data from previous absorption studies
with the same meal.
Study design. On days 1 and 2, the fasting subjects
consumed labelled test meals (described below) fed
under standardised conditions and close supervision. On
one day, the subjects consumed the labelled test meal
with 4 mg 58Fe as FS, and on the other day, they consumed
the same test meal labelled with 4 mg 57Fe as FPP, added to
the meal at the time of serving. The order of the test meals
was randomised across subjects. Deionised water (200 g)
was served with the meal. No intake of food and
fluids was allowed for 4 h after the test meal intake.
At day 16, a fasting blood sample was obtained. If the
subjects were taking vitamin/mineral supplements or any
other medications other than oral contraceptives, these
were stopped for 2 weeks before the study and until the
final venepuncture. The present study was conducted
according to the guidelines laid down in the Declaration
of Helsinki, and all procedures were approved by the
review committee at ETH Zu¨rich. Written informed consent
was obtained from all subjects.
Test meal. The test meal was boiled white rice (50 g dry
weight) and 25 g (fresh weight) vegetable sauce. The sauce
(44 % Chinese cabbage, 22 % carrots, 22 % zucchini and
13 % onions) was produced by boiling the vegetables until
tender, stir-frying in vegetable oil and then pure´eing. All
ingredients were purchased in bulk and used for the entire
study. The food portions were kept frozen until use, and
each portion was microwaved on the day of feeding.
Isotopic analyses. 58Fe-labelled FS was prepared from
isotopically enriched 58Fe (Chemgas, Boulogne, France)
by dilution in 0·1 M-H2SO4.
57Fe-labelled FPP was produced
by Paul Lohmann GmbH (Emmerthal, Germany). The
isotopic composition of the stable isotope labels was
measured by negative thermal ionisation MS(7,8). Enrich-
ment of the isotopic labels was 97·82 % for 57Fe and
92·86 % for 58Fe. Each isotopically enriched blood sample
was analysed in duplicate for its Fe isotopic composition
by negative thermal ionisation MS using a magnetic
sector field mass spectrometer (MAT 262) equipped with
a multi-collector system for simultaneous ion beam detec-
tion(7,8). Data were normalised for the natural 56Fe:54Fe
isotope ratio(9) to correct for mass-dependent fractionation
effects in the ion source. Based on the shift of the Fe iso-
tope ratios in the blood samples and the amount of Fe cir-
culating in the body, the amounts of 57Fe and 58Fe isotopic
label present in the blood 14 d after the test meals were
calculated by isotope dilution(8). Circulating Fe was
calculated based on the blood, height and weight accor-
ding to Brown et al.(10). For the calculation of fractional
absorption, 80 % incorporation of the absorbed Fe into
erythrocytes was assumed.
Study 2: efficacy studies
Subjects and study design. We did a secondary analysis of
two previous efficacy studies of the Fe fortification of
iodised salt in northern Morocco, one using FS and another
using FPP. The methods and results have been described
in detail previously(11,12). In the FS study, Fe was added
at a level of 1 mg/g salt using microencapsulated FS
(Cap-Shure FS-165E-50; Balchem, Slate Hill, NY, USA)(11).
In the FPP study, Fe was added as micronised FPP (article
no. 3043448; Dr Paul Lohmann) at a fortification level of
2 mg Fe/g salt(12). The fortification level was set higher
because the RBV of FPP is estimated to be approximately
50 % of FS(3).
The design of the two studies was similar. For both studies
(1) the salt came from the same local source and was iodised
with potassium iodide at 25mg/g salt, (2) 2 kg of salt was dis-
tributed to the participating households monthly for 10
months and (3) the subjects were 6- to 15-year-old children
from the same neighbouring primary schools. The studies
were done approximately 2 years apart(11,12). The studies
were conducted according to the guidelines laid down in
the Declaration of Helsinki, and all procedures were
approved by the review committee at ETH Zu¨rich and the
Ministry of Health in Rabat. Oral informed consent was
obtained from all parents of the children. The studies
included both Fe-deficient and Fe-sufficient children
because all children in the schools were invited to partici-
pate in the studies. The children were randomised at the
household level into two groups. One group was given
iodised salt as a control, while the second group was
given the dual-fortified salt with Fe and iodine; the results
from the children who received the dual-fortified salt are
reported here. At baseline, weight and height were
measured, and whole blood was collected by venepuncture
M. B. Zimmermann et al.1246
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
for the determination of Hb, serum ferritin (SF) and serum
transferrin receptor (sTfR). In both studies, these measures
were repeated 10 months later(11,12).
Laboratory analysis
Study 1. Hb was measured in whole blood on the day of
collection using an automated coulter counter (AcT8 Coul-
ter; Beckman Coulter, Krefeld, Germany) with three-level
control materials provided by the manufacturer. The
plasma was separated and frozen until analysis. Plasma fer-
ritin was measured on an IMMULITEw automatic system
(DPC Bu¨hlmann GmbH, Aschwil, Germany); the normal
range was 15–300mg/l. High-sensitivity C-reactive protein
was measured by using IMMULITE; the normal range
was , 100 mg/l.
Study 2. Hb was measured as above using a Coulter
counter. SF and sTfR were measured using an ELISA
(Ramco, Houston, TX, USA). Normal reference values
are as follows: SF, 12–300mg/l; sTfR, 2·9–8·5 mg/l.
Fe deficiency was defined as either SF , 12mg/l or
sTfR . 8·5 mg/l(1). Anaemia was defined as Hb ,120 g/l
in children aged $12 years, and Hb ,115 g/l in children
aged 5–11 years(13). Body Fe was estimated by the
method of Cook et al.(14) using the following formula:
Body Fe ðmg=kgÞ ¼ 2ðlogðsTfR=SFÞ2 2·8229Þ=0·1207:
The change in body Fe during the efficacy study was
obtained by subtracting the baseline body Fe value from
the value at 40 weeks.
Data analysis
Data were analysed using SPSS 13.0 for Windows (SPSS,
Chicago, IL, USA) and Excel (XP 2002; Microsoft, Seattle,
WA, USA). Results are presented as means and standard
deviations if normally distributed. If not normally distribu-
ted, results are presented as medians (ranges) and log-
transformed for comparisons. The x 2 and unpaired t tests
were used for comparisons between the groups, and
trend line slopes and regressions were done to examine
relationships among the variables. P values ,0·05 were
considered to be significant.
Results
Table 1 shows the characteristics of the subjects in the low
Fe status and Fe-sufficient groups. In the low Fe status
group, 66 % of women were Fe deficient (plasma
ferritin , 15mg/l) and 18 % were Fe-deficient anaemic.
In the Fe-sufficient group, Hb and plasma ferritin were
significantly higher (P,0·05 and P,0·0001), while Fe
bioavailability from the FS-labelled meal was significantly
lower (P,0·01). However, there was no significant
difference in Fe bioavailability from FPP between the
Fe-sufficient and low Fe status groups (Table 1). T
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Fig. 1(a) shows the relationships between plasma ferritin
and Fe bioavailability from the FS- and FPP-labelled meals.
Plasma ferritin was a significant negative predictor of
Fe bioavailability from the FS-labelled meal (r 2 0·386;
P,0·0001) but not from the FPP-labelled meal. The slope
of the trend line for FS was significantly steeper than that
of FPP (P,0·01). As shown in Fig. 1(b), plasma ferritin
was a significant positive predictor of the RBV of FPP
(r 2 0·156; P,0·01).
Table 2 shows the characteristics of the children in the
two efficacy studies. There were no significant differences
between the groups except that the group that received the
FS-fortified salt had a higher prevalence of Fe-deficiency
anaemia (P,0·05).
Fig. 2 shows the relationship between body Fe at base-
line, calculated from the sTfR:SF ratio, and the change in
body Fe during the 10-month studies. Body Fe at baseline
was a stronger negative predictor of the change in body Fe
during the intervention with FS (r 2 0·467; P,0·0001) than
with FPP (r 2 0·169; P,0·01). The slope of the trend line for
FS was significantly steeper than that of FPP (P,0·05).
Discussion
FPP is often used to fortify infant cereals and chocolate
drink powders(2). Its main advantage is that it causes no
adverse colour and flavour changes. However, it is
poorly soluble in both water and dilute acid, including gas-
tric juice, and is variably absorbed. Human studies have
reported absorption values of 20–75 % relative to FS
depending on food processing, particle size of the fortifica-
tion and crystal structure(2). The RBV of FPP (8·3–12·8 %) in
the present study is somewhat lower than that reported in
previous studies, but is generally consistent with previous
results using FPP in rice-based meals(6,15). However,
the efficacy of FPP has been demonstrated in salt and
rice fortification(12,15–17).
Moretti et al.(6) used a dispersible form of submicro-
metre-sized FPP in a cross-over design to measure Fe bioa-
vailability in young women (n 26) from a wheat-milk infant
cereal given with and without ascorbic acid (n 10) and
from a processed and unprocessed rice meal (n 16). Of
the twenty-six subjects, sixteen were Fe deficient. There
was a significant negative correlation between SF and the
absorption of FPP from the infant cereal with and without
ascorbic acid (r 20·77, P¼0·010; r 20·64, P¼0·046,
respectively), but in the rice meals, there was no significant
relationship. Combining all data, Fe status was a highly sig-
nificant positive predictor of the RBV of FPP (r 0·64;
P,0·001)(6). In the present study, in women selected for
a broader range of Fe status, including 18 % with Fe-
deficiency anaemia, Fe status was again not a significant
Table 2. Baseline characteristics of the Moroccan children in the
efficacy studies who received either iodised salt fortified with ferric
pyrophosphate (FPP) or ferrous sulphate (FS)
(Mean values, standard deviations, medians, ranges, number of
children and percentages)
Characteristics
Salt fortified with FPP
(n 75)
Salt fortified with FS
(n 183)
Age (years)
Mean 10·8 10·4
SD 2·3 2·5
Sex
Female 35 89
Male 40 94
Wt (kg)
Mean 31·2 29·5
SD 9·9 9·1
Ht (m)
Mean 1·34 1·33
SD 0·14 0·17
Hb (g/l)
Mean 113 113
SD 10 13
Serum ferritin (mg/l)
Median 16 20
Range 6–28 1–79
Serum transferrin receptor (mg/l)
Median 7·6 8·6
Range 3·8–17·8 4·3–17·1
Body Fe (mg/kg)
Median 1·58 2·07
Range 24·35–7·19 217·10–6·47
Prevalence of Fe-deficiency anaemia
Children (n) 31 64
% 23* 35
* Value was significantly different from the FS group (P,0·05; x 2 test).
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Fig. 1. (a) Relationships between plasma ferritin and Fe bioavailability from
the ferrous sulphate- and ferrous fumarate-labelled rice-based test meals.
Ferrous sulphate: y ¼ 20·4228x þ 1·6378; r 2 0·3859 and ferrous
pyrophosphate: y ¼ 20·1608x þ 0·2976; r 2 0·0514. (b) Relationships
between plasma ferritin and Fe bioavailability from the ferrous sulphate- and
ferric pyrophosphate-labelled meals. The subjects were forty-nine women
selected for a range of Fe status, from Fe-deficiency anaemia to Fe suffi-
ciency. y ¼ 0·2312x þ 0·7191; r 2 0·1558.
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predictor of Fe bioavailability from the commercial form of
FPP commonly used as a food fortificant, and there was no
significant up-regulation of Fe absorption from FPP in Fe
deficiency. Because of this, Fe status was a significant
direct predictor of the RBV of FPP (r 2 0·22), although the
prediction was less strong than in the Moretti et al.
study(6) (r 2 0·37).
In healthy adults without inflammation, the two main
physiological stimuli that increase dietary Fe absorption
are a decrease in body Fe stores and an increase in erythro-
poiesis(5). Fe absorption is inversely proportional to Fe
status in humans over a wide range of body Fe stores,
whether stores are measured directly or represented by
SF, in both adults(4,18,19) and children(20–22). However, in
all of these studies, only water-soluble forms of Fe (FS, fer-
rous ascorbate and/or ferric citrate) were used to examine
the relationship between Fe status and Fe absorption. The
present study is the first designed to directly compare the
effect of Fe status on the bioavailability of a poorly soluble
Fe compound. A strength of the study was the selection of
subjects with a wide range of Fe status, from clear Fe
sufficiency to Fe-deficiency anaemia. This is important as
dietary Fe absorption rises only slowly as storage Fe
is depleted, but rises steeply as Fe supply to the marrow
is compromised(23).
Non-haem Fe liberation from foods during digestion
produces ferrous (Fe2þ) and ferric (Fe3þ) iron; the
equilibrium of these in the gut depends on the reducing
power of the meal and other luminal factors, such as the
gastric pH(2). Ferric iron can be converted to the ferrous
form by food components (such as ascorbic acid) and/or
the duodenal ferric reductase, duodenal cytochrome b,
on the apical surface of the duodenal enterocyte(24). Fer-
rous iron, but not ferric iron, is transported into the enter-
ocyte by the apical Fe transporter divalent metal transport
protein 1 (DMT1)(24). In duodenal biopsy specimens in
human subjects, Fe deficiency results in a 4- to 12-fold
increase in DMT1 expression v. normal controls(25–27).
In these studies, DMT1 levels show significant inverse
correlations with SF. In contrast, the effect of Fe status
on duodenal cytochrome b expression in humans is
unclear(25,26,28). Several studies have reported no signifi-
cant up-regulation in Fe deficiency(25,28). Therefore, the
stronger up-regulation of Fe absorption from FS compared
with FPP in Fe deficiency may be at least partially
explained as follows: in Fe-sufficient subjects, low
expression of DMT1 becomes an important limiting factor
in Fe absorption, reducing differences in absorption due
to the varying solubility of the Fe compounds. But
duodenal cytochrome b expression is not down-regulated,
allowing available ferric iron to be converted to the ferrous
form for absorption. In Fe deficiency, DMT1 is strongly
up-regulated(25,26,28) and there is ample DMTI on the
apical surface, allowing solubility to emerge as the princi-
pal limiting factor in Fe absorption. At the same time,
duodenal cytochrome b is not strongly up-regulated(25,28),
further favouring the absorption of ferrous iron over
ferric iron.
Our data suggest that Fe absorption from poorly soluble
Fe compounds such as FPP (and possibly elemental Fe
compounds) is less well up-regulated by Fe deficiency
than Fe absorption from soluble Fe compounds such as
FS. Our findings should be confirmed in young children,
where the superior organoleptic properties of FPP may
be an important consideration. However, they argue that
FS should continue to be recommended for the fortification
of foods in Fe-deficient populations, while the use of FPP
may be less desirable. Compared with poorly soluble com-
pounds, more soluble Fe compounds not only demonstrate
better overall absorption and can be used at lower fortifica-
tion levels, but they also may have the added advantage
that, because their absorption is up-regulated in Fe
deficiency, they innately ‘target’ Fe-deficient individuals
in a population.
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